Curis (CRIS) Reports Encouraging Emavusertib Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
June 4, 2022 9:00 AM EDTTakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses
Potential for overcoming ibrutinib resistance demonstrated with a complete response in a patient who had prior treatment with ibrutinib
TakeAim Leukemia data, top-line data previously released in January, highlight emavusertib's single-agent activity in heavily pretreated AML and HR-MDS patients
LEXINGTON, Mass., June 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:... More
